Overview

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2014-10-27
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events (AEs) and laboratory abnormalities.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Antibodies, Monoclonal